What the Real-World Data Shows About Omnipod 5

Omnipod 5 is a hybrid closed-loop automated insulin delivery (AID) system. That means it combines an insulin pump, a continuous glucose monitor, and a software algorithm that automatically adjusts insulin delivery based on real-time glucose readings. However, it's not fully automatic—users still make decisions about meals, activity, and their glucose targets.

The system gives users flexibility in setting their target glucose range, typically between 110 and 150 mg/dL in 10 mg/dL increments. This personalization is important: the target someone chooses affects how the algorithm works and what results they see.

A study published in 2024 analyzed data from 69,902 people using Omnipod 5 in the United States—the largest real-world look at how the system performs outside clinical trials. Researchers examined glucose targets users actually chose and the outcomes they achieved.

Users who set their average glucose target at 110 mg/dL achieved a median time in range (glucose between 70–180 mg/dL) of 68.8%. Those targeting 120 mg/dL reached 61.3%, and those targeting 130–150 mg/dL achieved 53.6%. Time below 70 mg/dL (low blood sugar) was minimal across all groups—less than 1.13% in the median user.

Younger users tended to use multiple or higher glucose targets, while adults using the lowest target (110 mg/dL) achieved time in range of 69.9%—notably higher than children and adolescents, who averaged 65.0%.

A 2024 comparison of different hybrid closed-loop systems found that all of them—including Omnipod 5—significantly increased time in range compared to standard insulin therapy without continuous glucose monitoring. The systems ranked differently by performance, but all reduced time spent below target glucose levels, an important safety marker.

Omnipod 5 was among the systems studied, though other systems (like Minimed 780G) showed slightly higher time in range in clinical trials. However, real-world results often differ from controlled study conditions, and individual outcomes depend heavily on how well a person's settings match their unique needs.

Hybrid closed-loop systems, including Omnipod 5, have been studied in pregnant people with Type 1 diabetes. In a recent UK trial, those using hybrid closed-loop therapy achieved 68.2% time in target range during pregnancy (63–140 mg/dL) compared to 55.6% with standard insulin therapy—a clinically meaningful difference. Safety data showed no increased risk of severe hypoglycemia or other serious events.

Ongoing real-world registries are continuing to gather long-term safety and effectiveness data from Omnipod 5 users across age groups and in diverse clinical settings. This information helps clinicians understand how to optimize the system for individual people and identify any emerging patterns.

If you're considering or using Omnipod 5, the evidence shows that real-world outcomes center around 65–70% time in range for most users—which aligns with clinical trial results. Your actual outcomes will depend on your glucose target setting, how consistently you use the system, and how well your personal settings match your lifestyle and physiology.

Because results vary significantly based on individual choices and circumstances, working closely with your diabetes care team to personalize your settings is essential. The system is designed to work with you, not replace your judgment about meals, exercise, and other daily decisions.

Origin: YouTube / She's Diabetic (Video report). Evidence: Video report, corroborated with 6 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.